<DOC>
	<DOCNO>NCT01980342</DOCNO>
	<brief_summary>This study evaluate whether interaction etonogestrel , progestin hormone release contraceptive implant Nexplanon , efavirenz , common medication use treat HIV . The endpoint measure study help determine interaction lead decrease contraceptive efficacy contraceptive implant .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Etonogestrel Contraceptive Implant When Co-administered With Efavirenz</brief_title>
	<detailed_description>Women make nearly half world 's HIV-infected population , many woman HIV reproductive age . There grow need provide effective contraception woman want need protect pregnancy . However , concern decrease contraceptive efficacy woman antiretroviral therapy rely hormonal contraception due drug-drug interaction . Of particular concern possible interaction etonogestrel , active hormone long-acting reversible contraceptive implant . We propose pilot study evaluate effect efavirenz ( EFV ) , commonly use non-nucleoside reverse transcriptase inhibitor , pharmacokinetics etonogestrel implant . We recruit 18 healthy woman implant place 12 24 month . They ask take two-week course efavirenz . During two week four additional week , monitor semi-weekly etonogestrel concentration , serum , ultrasound , cervical mucus marker ovulation . We also assess efavirenz concentration baseline end two-week treatment course . We derive pharmacokinetic parameter compare concentration across time point . Results help inform design large study , similar study different antiretroviral medication . We hypothesize take efavirenz use etonogestrel contraceptive implant result increase incidence ovulation .</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<criteria>Healthy woman age 1840 year Nexplanon®/Implanon® place palpable exam , device place 12 24 month prior enrollment , provide documentation implant place Able speak read English Documented HIVnegative status within 30 day enrollment BMI 18.5 24.9 kg/m2 Willingness take twoweek course efavirenz Willingness comply study visit schedule ( describe ) , include blood sampling , transvaginal ultrasound , cervical mucus assessment Negative urine human chorionic gonadotropin pregnancy test study entry Normal laboratory value within 30 day study entry , specify : White blood cell count ≥ 4500 ≤ 11000 cells/mm3 Platelet count ≥ 100,000 platelets/mm3 Hemoglobin ≥ 8.0 g/dL International normalized ratio ( INR ) ≤ 1.8 Aspartate transaminase ( SGOT ) alanine aminotransferase ( SGPT ) ≤ 3 time upper limit normal ( ULN ) ( upper limit normal ) Creatinine ≤ 1.5 x ULN Serum amylase ≤ 1.5 x ULN Total bilirubin ≤ 2.0 x ULN Agree use additional reliable method contraception participate study . Acceptable method include : Abstinence Condoms ( male female ) without spermicide Preexisting sterilization subject male partner Willingness abstain alcohol consumption study period Willingness abstain grapefruit product supplement duration study . Breastfeeding Hypersensitivity efavirenz History seizure disorder Initiated , discontinue , change dos drug cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) inducer inhibitor within 30 day study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Long act reversible contraception</keyword>
	<keyword>HIV</keyword>
</DOC>